Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trodelvy | sacituzumab govitecan | HR+, HER2− advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
| N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Active | ||
| Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Active | ||
| Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Active | ||
| Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Active | ||
| Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
| Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Active |
Last Updated : April 25, 2024